Equities

Flerie AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Flerie AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)35.60
  • Today's Change-0.10 / -0.28%
  • Shares traded14.69k
  • 1 Year change-25.86%
  • Beta-0.0134
Data delayed at least 15 minutes, as of Feb 10 2026 17:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Flerie AB, formerly InDex Pharmaceuticals Holding AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is an active long-term global biotech and pharmaceutical investor that managing a portfolio of companies in Europe, Israel, and the US. Flerie invests in companies across the entire value chain, providing exposure to opportunities across three segments: Product Development, Commercial Growth, and Limited Partnerships. The Product Development segment consists of early-stage biotech and pharma companies in product development. The Commercial Growth segment consists of companies that are already selling products or services and showcasing proof-of-concept with high growth and some that have already reached profitability. The Limited Partnerships segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerie’s investment portfolio.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-757.00m
  • Incorporated2016
  • Employees2.00
  • Location
    Flerie ABSkeppsbron 16STOCKHOLM 111 30SwedenSWE
  • Phone+46 812203850
  • Fax+46 850884739
  • Websitehttps://www.flerie.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
FLERIE:STO since
announced
Transaction
value
Lipum ABAnnounced18 Nov 202518 Nov 2025Announced-7.29%15.24m
Toleranzia ABDeal completed25 Mar 202525 Mar 2025Deal completed-19.09%4.53m
Data delayed at least 15 minutes, as of Feb 10 2026 17:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Dicot Pharma AB126.00k-84.00m621.89m4.00--6.89--4,935.65-0.0459-0.04590.000070.04490.00110.680.037142,000.00-69.50-94.78-75.43-111.46-61,341.27-32,616.05-66,663.49-37,576.058.82--0.00---88.60-47.16-30.66------
Infant Bacterial Therapeutics AB0.00-79.73m760.26m10.00--6.33-----5.92-5.920.009.230.00----0.00-38.19-22.82-48.56-24.41------------0.00-------11.24------
Cinclus Pharma Holding publ AB48.42m-177.05m801.38m19.00--1.90--16.55-3.80-3.801.049.070.0777--15.473,724,539.00-28.43---32.01-------365.65------0.0197---23.14--21.89------
Vistin Pharma ASA424.51m72.86m827.76m77.0011.362.848.901.951.761.7610.267.051.121.876.20--19.201.6523.641.9966.4062.2817.161.881.16--0.063---1.4513.5637.62-1.0317.32--
Arcticzymes Technologies ASA96.20m7.15m1.03bn55.00147.503.3466.8410.700.14640.14641.976.470.29670.2951.911,874,073.002.2013.282.3214.3995.4296.207.4331.4115.45--0.01840.00-12.2618.22-56.40--53.98--
Orexo AB386.40m-201.10m1.03bn72.00--2.10--2.68-5.8018.4211.1514.220.40731.292.025,366,667.00-21.20-28.03-29.75-42.5789.9683.88-52.04-74.893.70-3.000.5005---12.46-47.6915.63------
SynAct Pharma AB0.00-106.27m1.10bn8.00--5.64-----2.20-2.200.003.650.00----0.00-45.16-85.38-50.22-99.19-----------63.960.0071------61.82------
Photocure ASA501.75m1.98m1.66bn101.00812.523.5956.683.310.08090.080920.0018.290.75871.158.115,322,683.000.2993-3.650.3389-4.1992.8394.000.3945-6.263.87--0.00--4.9413.29-441.16--65.53--
Flerie AB0.00-757.00m2.76bn2.00--0.8166-----9.76-9.760.0043.600.00-------19.86-18.21-19.95-18.51---367.55---1,314.83---0.04890.0006---100.00---231.97------
Swedencare AB (publ)2.67bn63.00m3.86bn609.0060.990.564610.331.440.3960.39616.7842.770.27883.639.864,776,250.000.65361.160.67951.2033.6036.002.344.401.523.940.201544.568.6282.0968.7727.0269.3912.30
BioGaia AB1.46bn315.92m10.74bn238.0034.909.0536.957.343.123.1214.4612.040.8623----6,499,662.0018.6314.7620.8916.0372.7173.0621.6027.38----0.00129.549.7313.11-3.8213.40-18.3633.95
Bonesupport Holding AB1.12bn151.92m11.78bn143.0078.1914.2972.5810.532.292.2916.8312.521.260.62056.268,811,984.0017.065.1420.116.3192.6191.4013.575.593.9219.360.01330.0052.0542.04-45.41--5.71--
Data as of Feb 10 2026. Currency figures normalised to Flerie AB's reporting currency: Swedish Krona SEK

Institutional shareholders

19.47%Per cent of shares held by top holders
HolderShares% Held
Atlant Fonder ABas of 31 Dec 20248.13m10.49%
Fj�rde AP-fondenas of 31 Dec 20245.46m7.05%
Handelsbanken Fonder ABas of 31 Dec 2024992.69k1.28%
SEB Funds ABas of 31 Dec 2025330.22k0.43%
Storebrand Asset Management ASas of 30 Nov 2025145.34k0.19%
Skandia Investment Management ABas of 28 Nov 202521.97k0.03%
Skandia Fonder ABas of 28 Nov 20252.23k0.00%
More ▼
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.